Guide

Allergen Control in Supplement Manufacturing: FALCPA/FASTER, Validated Cleaning, Shared-Line Controls and the Precautionary-Advisory Question

Allergen control is the single most common cause of US supplement recalls and the costliest one. The Food Allergen Labeling and Consumer Protection Act (FALCPA 2004) and the FASTER Act (2021, adding sesame) require declaration of the 'big 9' major food allergens — milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, sesame — on every supplement label where the allergen is intentionally present. Beyond labelling, the operational hard part is shared-line manufacturing: a vitamin facility runs a soy-containing product on Monday and a non-soy product on Tuesday on the same blender, the cleaning validation is the difference between a Class I recall and a clean release. This guide maps the FALCPA/FASTER labelling regime, the cleaning validation discipline, the precautionary-advisory question and the operating posture for shared-line supplement facilities.

Start free trial Free trial, no credit card, onboard in days, not months.

FALCPA, FASTER and the big-9 — labelling done right

FALCPA 2004 and FASTER 2021 require the 'big 9' major food allergens to be declared on the supplement label whenever they are present as an intentional ingredient — milk, eggs, fish, crustacean shellfish, tree nuts (with the specific tree nut named), peanuts, wheat, soybeans, sesame. Declaration uses either the 'Contains' statement following the ingredient list ('Contains: Milk, Soy') or the parenthetical-source format within the ingredient list ('Casein (milk)'). The allergen must be declared if the supplement contains it intentionally, regardless of quantity — there is no threshold below which intentional inclusion can be omitted. The declaration is in the common allergen name (milk, not casein; egg, not lysozyme), as the consumer reads the label, not as the chemist writes the ingredient. Failure to declare an intentional allergen is a Class I (life-threatening) recall trigger and the recurring driver of FDA-mandated recall announcements.

Cleaning validation — the shared-line evidence chain

Shared-line allergen risk is the manufacturing reality of most supplement facilities. A blender, a coater, an encapsulator, a tablet press, a bottling line — all routinely run sequential lots with different allergen profiles. The 21 CFR 111 GMP cleaning expectation, and the 455-2 / USP <2750> uplift, requires validated cleaning — not just a cleaning SOP and a visual inspection. Validation generates evidence that the cleaning procedure achieves a defined acceptance limit for allergen residue on equipment surfaces and in equipment rinse water, typically expressed as an ADI (Acceptable Daily Intake) / Health-Based Exposure Limit driven by the lowest published No Observed Adverse Effect Level (NOAEL) for sensitised individuals, the next product's safe daily dose and the shared-equipment surface area. Routine verification is the per-changeover swab test against the validated acceptance limit, typically by allergen-specific ELISA for the residual allergen of concern.

Supplier-derived allergen risk — and the BOM-deep view

Allergen risk does not begin at the manufacturing facility. Many recurring supplement allergen recalls trace back to supplier-derived contamination: an excipient supplier swaps from a non-allergen carrier to a soy-derived one and does not flag the change, a botanical supplier processes the botanical on a peanut-shared line, a flavour house base contains undeclared milk. The FDA Reportable Food Registry historically shows allergen as the dominant cause of supplier-driven recalls. Defensible posture requires the supplier qualification questionnaire to cover all big-9 allergens at the supplier's facility (in-spec, shared-line, contained-but-controlled), the supplier change notification to require pre-notice of any allergen-status change, and the receiving sampling to include allergen ELISA where the supplier's allergen status would be a recall-trigger surprise.

The precautionary advisory question — 'May contain' and when to use it

The precautionary advisory statement ('May contain milk', 'Manufactured in a facility that processes peanuts') is voluntary, not required by FALCPA — and FDA's position is that it should be used only where unintentional cross-contact is genuinely possible despite GMP and validated cleaning. Overuse undermines the warning's value: a supplement labelled 'may contain' every big-9 allergen becomes useless to the allergic consumer because nothing is safe. Underuse, where real cross-contact risk exists without a validated cleaning programme, is the recall risk. The defensible practice: cleaning validation eliminates the cross-contact risk where the science supports it, and 'may contain' applies only where validated cleaning is not feasible or where a specific allergen risk remains documented. The Threshold of Regulation work (Reference Doses from Allergen Bureau VITAL programme) increasingly informs the decision.

Operating posture — programme, recall readiness and FDA inspection response

Six-point allergen posture. (1) Big-9 status on every ingredient and finished SKU, with sesame added to legacy records under FASTER 2021. (2) Validated cleaning per equipment per allergen, with health-based acceptance limits and per-changeover swab verification by allergen ELISA. (3) Supplier qualification covering supplier allergen profile and shared-line status, with change-notification clauses. (4) Label allergen-declaration generated from the BOM, with print-release gate. (5) Mock recall on an allergen scenario at least annually, with traceback time measured. (6) FDA inspection response file — cleaning validation reports, swab records, supplier change history, label declaration evidence, mock recall results, recall-readiness procedure — ready to open, not assembled under pressure.

Standards covered in this guide

Each standard, retailer code or assurance scheme referenced above has its own deep-dive page with scope, audit detail and common pitfalls.

Allergen Control

The programme covering big-9 allergen labelling, validated shared-line cleaning, BOM-deep allergen flags and the precautionary-advisory decision — the dominant cause of US supplement recalls.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Validated cleaning per equipment per allergen

Health-based acceptance limit, per-changeover ELISA swab evidence.

BOM-deep allergen flags and label generation

'Contains' statement derived from BOM, print-release gated.

Mock recall and FDA inspection readiness

Allergen scenario traceback timed and recorded annually.

Industries this hits hardest

Dietary supplements

Frequently asked

What allergens must I declare on a US supplement label?

The big 9: milk, eggs, fish, crustacean shellfish, tree nuts (with the specific tree nut named), peanuts, wheat, soybeans and sesame (added by the FASTER Act 2021). Declaration uses either the 'Contains: …' statement following the ingredient list or the parenthetical-source format in the ingredient list. Declaration is required whenever the allergen is intentionally present, regardless of quantity.

Is 'may contain' required when allergens are processed on the same line?

No. The precautionary advisory ('may contain', 'processed in a facility that also processes…') is voluntary under FALCPA. FDA's position is that it should be used only where unintentional cross-contact is genuinely possible despite GMP and validated cleaning. Validated cleaning that eliminates the cross-contact risk supports omitting the advisory; absence of validated cleaning where risk is real is the recall exposure.

What is validated cleaning vs verified cleaning?

Verified cleaning means the cleaning SOP was followed and a visual or simple-test check confirmed equipment is visually clean. Validated cleaning means the cleaning procedure has been demonstrated, with statistical confidence, to reduce the allergen residue to or below a health-based acceptance limit on equipment surfaces and in rinse water — typically through three-batch validation studies with allergen-specific ELISA swab analysis. 21 CFR 111 and the retailer-grade standards (455-2, USP <2750>) expect validated cleaning for allergens.

How does sesame change my legacy allergen programme?

The FASTER Act 2021 added sesame as the ninth major allergen effective 1 January 2023. Every legacy ingredient and SKU record must be screened for sesame presence (intentional or shared-line) and the label updated where sesame is intentionally present. Suppliers must be re-questioned on sesame status. Cleaning validation should be expanded to cover sesame on any line where sesame-containing product is or was run. Many supplement brands hit recall risk on this transition because legacy BOMs did not track sesame.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →